A Phase I/II Study of the Combination of Oral Rigosertib and Azacitidine in Patients with Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML)

被引：3
|
作者：
Navada, Shyamala C. [1 ]
Garcia-Manero, Guillermo [2 ]
Wilhelm, Francois [3 ]
Hearn, Katherine [2 ]
Odchimar-Reissig, Rosalie [1 ]
Demakos, Erin P. [1 ]
Alvarado, Yesid [2 ]
Daver, Naval [2 ]
DiNardo, Courtney D. [2 ]
Konopleva, Marina [2 ]
Borthakur, Gautam [2 ]
Azarnia, Nozar
Silverman, Lewis R. [1 ]
机构：
[1] Icahn Sch Med Mt Sinai, New York, NY 10029 USA
[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[3] Onconova Therapeut Inc, Newtown, PA USA
来源：
BLOOD | 2014年 / 124卷 / 21期
关键词：
D O I：
10.1182/blood.V124.21.3252.3252
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [21] A phase I/II study of the combination of quizartinib with azacitidine or low-dose cytarabine for the treatment of patients with acute myeloid leukemia or myelodysplastic syndrome
    Swaminathan, Mahesh
    Kantarjian, Hagop M.
    Levis, Mark
    Guerra, Veronica
    Borthakur, Gautam
    Alvarado, Yesid
    DiNardo, Courtney D.
    Kadia, Tapan
    Garcia-Manero, Guillermo
    Ohanian, Maro
    Daver, Naval
    Konopleva, Marina
    Pemmaraju, Naveen
    Ferrajol, Alessandra
    Andreeff, Michael
    Jain, Nitin
    Estrov, Zeev
    Jabbour, Elias J.
    Wierda, William G.
    Pierce, Sherry
    Pinsoy, Maria Rhona
    Xiao, Lianchun
    Ravandi, Farhad
    Cortes, Jorge E.
    [J]. HAEMATOLOGICA, 2021, 106 (08) : 2121 - 2130
  • [22] Predictors Of Response To Rigosertib In Patients With a Myelodysplastic Syndrome (MDS) Or Acute Myeloid Leukemia (AML) Relapsing After Or Refractory To Hypomethylating Agents
    Navada, Shyamala C.
    Odchimar-Reissig, Rosalie
    Reddy, E. Premkumar
    Demakos, Erin P.
    Holland, James F.
    Wilhelm, Francois
    Silverman, Lewis R.
    [J]. BLOOD, 2013, 122 (21)
  • [23] Phase Ib/II combination study of APR-246 and azacitidine (AZA) in patients with TP53 mutant myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML)
    Sallman, David A.
    DeZern, Amy
    Sweet, Kendra
    Steensma, David P.
    Cluzeau, Thomas
    Sekeres, Mikkael
    Garcia-Manero, Guillermo
    Roboz, Gail
    McLemore, Amy
    McGraw, Kathy
    Puskas, John
    Zhang, Ling
    Bhagat, Chirag
    Graber, Armin
    Al Ali, Najla H.
    Padron, Eric
    Tell, Roger
    Lancet, Jeffrey E.
    Fenaux, Pierre
    List, Alan F.
    Komrokji, Rami S.
    [J]. CANCER RESEARCH, 2018, 78 (13)
  • [24] A Phase 1 Dose Escalation Study of Milademetan in Combination with 5-Azacitidine (AZA) in Patients with Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
    DiNardo, Courtney D.
    Olin, Rebecca
    Ishizawa, Jo
    Sumi, Hiroyuki
    Xie, Jingdong
    Kato, Kazunobu
    Kumar, Prasanna
    Andreeff, Michael
    [J]. BLOOD, 2019, 134
  • [25] Phase I/II study of vosaroxin and decitabine in older patients (pts) with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS).
    Daver, Naval Guastad
    Kantarjian, Hagop M.
    Pierce, Sherry
    Brandt, Mark
    Dinardo, Courtney Denton
    Pemmaraju, Naveen
    Vaughan, Kenneth
    Garcia-Manero, Guillermo
    Jabbour, Elias
    Borthakur, Gautam
    Kadia, Tapan M.
    Cortes, Jorge E.
    Craig, Adam
    Ravandi, Farhad
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [26] Phase I Study of Oral Azacitidine in Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, and Acute Myeloid Leukemia
    Garcia-Manero, Guillermo
    Gore, Steven D.
    Cogle, Christopher
    Ward, Renee
    Shi, Tao
    MacBeth, Kyle J.
    Laille, Eric
    Giordano, Heidi
    Sakoian, Sarah
    Jabbour, Elias
    Kantarjian, Hagop
    Skikne, Barry
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (18) : 2521 - 2527
  • [27] Phase I/II Study of Vosaroxin and Decitabine in Newly Diagnosed Older Patients (pts) with Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)
    Naval, Daver
    Kantarjian, Hagop M.
    Garcia-Manero, Guillermo
    Pemmaraju, Naveen
    Kadia, Tapan M.
    DiNardo, Courtney D.
    Jain, Nitin
    Borthakur, Gautam
    Jabbour, Elias
    Konopleva, Marina
    Cortes, Jorge E.
    Craig, Adam
    Ravandi, Farhad
    [J]. BLOOD, 2014, 124 (21)
  • [28] Phase II study of Mylotarg plus Troxatyl in patients with refractory acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS).
    Giles, FJ
    Garcia-Manero, G
    O'Brien, S
    Estey, E
    Kantarjian, H
    [J]. BLOOD, 2001, 98 (11) : 212B - 212B
  • [29] Symptom Burden In Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)
    Williams, Loretta A.
    Ault, Patricia S.
    Kantarjian, Hagop M.
    Garcia-Manero, Guillermo
    Quintas-Cardama, Alfonso
    Borthakur, Gautam
    Faderl, Stefan H.
    Jabbour, Elias J.
    Cleeland, Charles S.
    Cortes, Jorge E.
    [J]. BLOOD, 2013, 122 (21)
  • [30] Therapy of Myelodysplastic Syndrome (MDS) with azacitidine given in combination with etanercept: A phase II study
    Holsinger, Aaron L.
    Ramakrishnan, Aravind
    Storer, Barry
    Becker, Pamela S.
    Petersdorf, Stephen
    Deeig, H. Joachim
    Scott, Bart L.
    [J]. BLOOD, 2007, 110 (11) : 435A - 435A
12345